eicosapentaenoic acid ethyl ester has been researched along with Kidney Failure, Chronic in 2 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yorioka, N | 1 |
| Masaki, T | 1 |
| Ito, T | 1 |
| Kushihata, S | 1 |
| Nishida, Y | 1 |
| Taniguchi, Y | 1 |
| Oda, H | 1 |
| Yamakido, M | 1 |
| Ando, M | 1 |
| Sanaka, T | 1 |
| Nihei, H | 1 |
1 trial available for eicosapentaenoic acid ethyl ester and Kidney Failure, Chronic
| Article | Year |
|---|---|
Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients.
Topics: Administration, Oral; Adult; Aged; Arteriosclerosis; Drug Administration Schedule; Eicosapentaenoic | 1999 |
1 other study available for eicosapentaenoic acid ethyl ester and Kidney Failure, Chronic
| Article | Year |
|---|---|
Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Coagulation Factors; Drug Therapy, Combination; Eicosap | 2000 |